![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DALRD3 |
Gene summary for DALRD3 |
![]() |
Gene information | Species | Human | Gene symbol | DALRD3 | Gene ID | 55152 |
Gene name | DALR anticodon binding domain containing 3 | |
Gene Alias | DEE86 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0001510 | UniProtAcc | Q5D0E6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55152 | DALRD3 | LZE4T | Human | Esophagus | ESCC | 2.61e-07 | 1.25e-01 | 0.0811 |
55152 | DALRD3 | LZE7T | Human | Esophagus | ESCC | 1.15e-05 | 2.25e-01 | 0.0667 |
55152 | DALRD3 | LZE8T | Human | Esophagus | ESCC | 1.84e-03 | 6.83e-03 | 0.067 |
55152 | DALRD3 | LZE22T | Human | Esophagus | ESCC | 1.05e-04 | 2.63e-01 | 0.068 |
55152 | DALRD3 | LZE24T | Human | Esophagus | ESCC | 1.15e-03 | 1.97e-01 | 0.0596 |
55152 | DALRD3 | LZE21T | Human | Esophagus | ESCC | 1.70e-02 | 3.23e-01 | 0.0655 |
55152 | DALRD3 | P2T-E | Human | Esophagus | ESCC | 2.79e-13 | 1.77e-01 | 0.1177 |
55152 | DALRD3 | P4T-E | Human | Esophagus | ESCC | 3.63e-19 | 4.13e-01 | 0.1323 |
55152 | DALRD3 | P5T-E | Human | Esophagus | ESCC | 8.46e-21 | 1.41e-01 | 0.1327 |
55152 | DALRD3 | P8T-E | Human | Esophagus | ESCC | 4.67e-20 | 2.52e-01 | 0.0889 |
55152 | DALRD3 | P9T-E | Human | Esophagus | ESCC | 4.68e-15 | 2.00e-01 | 0.1131 |
55152 | DALRD3 | P10T-E | Human | Esophagus | ESCC | 3.73e-10 | 1.36e-01 | 0.116 |
55152 | DALRD3 | P11T-E | Human | Esophagus | ESCC | 3.17e-20 | 4.82e-01 | 0.1426 |
55152 | DALRD3 | P12T-E | Human | Esophagus | ESCC | 2.41e-18 | 3.26e-01 | 0.1122 |
55152 | DALRD3 | P15T-E | Human | Esophagus | ESCC | 5.83e-18 | 3.18e-01 | 0.1149 |
55152 | DALRD3 | P16T-E | Human | Esophagus | ESCC | 1.15e-23 | 4.54e-01 | 0.1153 |
55152 | DALRD3 | P20T-E | Human | Esophagus | ESCC | 1.10e-10 | 2.91e-01 | 0.1124 |
55152 | DALRD3 | P21T-E | Human | Esophagus | ESCC | 1.48e-26 | 5.36e-01 | 0.1617 |
55152 | DALRD3 | P22T-E | Human | Esophagus | ESCC | 4.47e-23 | 3.32e-01 | 0.1236 |
55152 | DALRD3 | P23T-E | Human | Esophagus | ESCC | 7.90e-15 | 2.30e-01 | 0.108 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
GO:00015101 | Esophagus | ESCC | RNA methylation | 58/8552 | 83/18723 | 6.87e-06 | 6.94e-05 | 58 |
GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:00304881 | Esophagus | ESCC | tRNA methylation | 30/8552 | 41/18723 | 3.27e-04 | 1.93e-03 | 30 |
GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
GO:000652011 | Liver | Cirrhotic | cellular amino acid metabolic process | 103/4634 | 284/18723 | 8.88e-06 | 1.30e-04 | 103 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DALRD3 | SNV | Missense_Mutation | rs761345101 | c.608A>G | p.Asn203Ser | p.N203S | Q5D0E6 | protein_coding | tolerated(0.68) | benign(0) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DALRD3 | SNV | Missense_Mutation | novel | c.908N>G | p.Asp303Gly | p.D303G | Q5D0E6 | protein_coding | tolerated(0.29) | benign(0.038) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DALRD3 | SNV | Missense_Mutation | novel | c.647N>A | p.Leu216Gln | p.L216Q | Q5D0E6 | protein_coding | deleterious(0) | possibly_damaging(0.713) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DALRD3 | SNV | Missense_Mutation | novel | c.650G>A | p.Cys217Tyr | p.C217Y | Q5D0E6 | protein_coding | tolerated(1) | benign(0.063) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DALRD3 | SNV | Missense_Mutation | novel | c.451N>G | p.Arg151Gly | p.R151G | Q5D0E6 | protein_coding | deleterious(0.02) | possibly_damaging(0.477) | TCGA-2Y-A9GV-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
DALRD3 | SNV | Missense_Mutation | c.64N>C | p.Gly22Arg | p.G22R | Q5D0E6 | protein_coding | tolerated(0.12) | probably_damaging(0.999) | TCGA-49-6767-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DALRD3 | SNV | Missense_Mutation | rs781227318 | c.493G>C | p.Asp165His | p.D165H | Q5D0E6 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-78-7220-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
DALRD3 | SNV | Missense_Mutation | c.589N>C | p.Glu197Gln | p.E197Q | Q5D0E6 | protein_coding | tolerated(0.27) | benign(0.019) | TCGA-22-5473-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD | |
DALRD3 | SNV | Missense_Mutation | novel | c.950N>C | p.Val317Ala | p.V317A | Q5D0E6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-60-2703-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
DALRD3 | SNV | Missense_Mutation | novel | c.1162N>A | p.Ala388Thr | p.A388T | Q5D0E6 | protein_coding | tolerated(0.47) | benign(0.057) | TCGA-66-2765-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |